Comparative Pharmacology
Head-to-head clinical analysis: ALLERFED versus MOTPOLY XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLERFED versus MOTPOLY XR.
ALLERFED vs MOTPOLY XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALLERFED is a combination of an antihistamine (fexofenadine) and a decongestant (pseudoephedrine). Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine effects, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor activation, causing vasoconstriction of nasal mucosa.
MOTPOLY XR is a combination of an opioid agonist (morphine) and an opioid antagonist (naltrexone). The extended-release formulation allows for sequential release: an initial morphine dose followed by naltrexone, which mitigates opioid-induced adverse effects by antagonizing mu-opioid receptors in the gastrointestinal tract without affecting central analgesia.
1 tablet (pseudoephedrine 60 mg / triprolidine 2.5 mg) orally every 4-6 hours; not to exceed 4 doses per 24 hours.
Adults: 10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life 20-24 hours; clinically significant for once-daily dosing in seasonal allergic rhinitis.
Terminal half-life 12–15 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily renal (approximately 60-70% as unchanged drug and metabolites); minor biliary (10-15%); fecal (5-10%).
Renal: ~60% unchanged; biliary/fecal: ~25% as metabolites; <5% unchanged in feces.
Category C
Category C
Decongestant
Decongestant/Antihistamine Combination